Timing of INR reversal using fresh-frozen plasma in warfarin-associated intracerebral hemorrhage

Intern Emerg Med. 2018 Jun;13(4):557-565. doi: 10.1007/s11739-017-1680-2. Epub 2017 Jun 1.

Abstract

Rapid reversal of coagulopathy is recommended in warfarin-associated intracerebral hemorrhage (WAICH). However, rapid correction of the INR has not yet been proven to improve clinical outcomes, and the rate of correction with fresh-frozen plasma (FFP) can be variable. We sought to determine whether faster INR reversal with FFP is associated with decreased hematoma expansion and improved outcome. We performed a retrospective analysis of a prospectively collected cohort of consecutive patients with WAICH presenting to an urban tertiary care hospital from 2000 to 2013. Patients with baseline INR > 1.4 treated with FFP and vitamin K were included. The primary outcomes are occurrence of hematoma expansion, discharge modified Rankin Scale (mRS), and 30-day mortality. The association between timing of INR reversal, ICH expansion, and outcome was investigated with logistic regression analysis. 120 subjects met inclusion criteria (mean age 76.9, 57.5% males). Median presenting INR was 2.8 (IQR 2.3-3.4). Hematoma expansion is not associated with slower INR reversal [median time to INR reversal 9 (IQR 5-14) h vs. 10 (IQR 7-16) h, p = 0.61]. Patients with ultimately poor outcome received more rapid INR reversal than those with favorable outcome [9 (IQR 6-14) h vs. 12 (8-19) h, p = 0.064). We find no evidence of an association between faster INR reversal and either reduced hematoma expansion or better outcome.

Keywords: Anticoagulants; Cerebral hemorrhage; Intracerebral hemorrhage; Stroke; Warfarin.

MeSH terms

  • Aged
  • Aged, 80 and over
  • Anticoagulants / adverse effects
  • Anticoagulants / therapeutic use
  • Antifibrinolytic Agents / pharmacology
  • Antifibrinolytic Agents / therapeutic use
  • Blood Component Transfusion / methods
  • Cerebral Hemorrhage / chemically induced
  • Cerebral Hemorrhage / drug therapy*
  • Cerebral Hemorrhage / etiology*
  • Chi-Square Distribution
  • Cohort Studies
  • Female
  • Humans
  • International Normalized Ratio / statistics & numerical data*
  • Male
  • Massachusetts
  • Middle Aged
  • Plasma / metabolism*
  • Retrospective Studies
  • Statistics, Nonparametric
  • Tomography, X-Ray Computed
  • Treatment Outcome
  • Vitamin K / pharmacology
  • Vitamin K / therapeutic use
  • Warfarin / adverse effects*
  • Warfarin / therapeutic use

Substances

  • Anticoagulants
  • Antifibrinolytic Agents
  • Vitamin K
  • Warfarin